Ticker
  • Companies
  • RNS
  • AI Chat
  • Research
  • Indices
  • Ticker TV
  • Events
  • Commodities
  • Currencies
Ticker
⌘K
Developer PortalNewsServices
/Equities/XLON/IBT
OverviewShare PriceRNSTradesShort InterestDirectorsHoldingsBuybacksTrust Data
International Biotechnology Trust PLC logo
International Biotechnology Trust PLC
/Equities/XLON/IBT
OverviewShare PriceRNSTradesShort InterestDirectorsHoldingsBuybacksTrust Data
International Biotechnology Trust PLC logo

International Biotechnology Trust PLC

Loading price data...
--
--

Price Chart

Open
988.77
High
992.00
Low
980.00
Close
988.53
Change
+6.00 (0.61%)
Volume
35,172

Recent RNS announcements

17 Apr 202610:57:11Net Asset Value(s)
16 Apr 202610:51:13Net Asset Value(s)
15 Apr 202611:36:43Net Asset Value(s)
14 Apr 202611:41:49Net Asset Value(s)
13 Apr 202611:51:43Net Asset Value(s)

Annual Reports

6 Nov 2025Annual Financial Report
5 Nov 2024Annual Financial Report
15 Nov 2022Annual Report

Directors (20+)

MP
Mr. P. J. DaviesDirector
–
LD
Lord Davies of AbersochDirector
–
MW
Mr. W. J. DaviesDirector
–
NM
N. M. RothschildDirector
–
MQ
Mr. Q. J. DaviesDirector
–

In the Press

8 Apr 2026Morning briefing: FTSE confirms Vietnams promotion to emerging market; Intl Biotechnology hails frenetic dealmaking” after Soleno bid; plus 3i GroupQuotedData
7 Apr 2026Boost for IBT as Soleno agrees takeoverSharesify
26 Mar 2026Morning briefing: SpaceX to file IPO prospectus; 3i falls on Action update; Intl Biotechnology boosted by Terns bid; Golden Prospect considers management proposalsQuotedData
10 Jul 2023Industry M&A remains a key driverHardman & Co.
8 Dec 2022Low FDA activity may drive further M&AHardman & Co.
30 Jun 2022M&A activity on the riseHardman & Co.
3 Dec 2021Access to fast-growing biotechnology companiesHardman & Co.
6 Jul 2021Investing in a broad spectrum of the drug industryHardman & Co.

Company details

The International Biotechnology Trust provides investors with an actively managed and diversified fund that enables them to tap into the rapidly expanding biotechnology industry.

Industry
Financials
Sector
Financial Services
LEI
213800N1QUJ744P76D11
Region
Europe
Admission date
6 May 1994
Website
ibtplc.com

Investment Trust · as at 30 Mar 2026

NAV per Share
927.45p
Discount/Premium
+6.5%

NAV History

Feb 2025–Jun 2025 · Daily

Shares details

Shares in issue
41,383,817
Total Voting Rights
31,827,834
Treasury Shares
9,555,983
Last updated: 17 April 2026

Recent Buybacks

02/04/2026
30,000£280,200
01/04/2026
30,000£278,014
25/11/2025
25,849£235,709
19/11/2025
100,000£902,680
11/11/2025
22,500£190,800

Instrument details

ISIN
GB0004559349
Exchange
XLON
Market
Main Market
Market Segment
SSMM
Market Sector
SSC5
Security Description
Ordinary Shares of 25p each; fully paid
Listing Category
Closed-ended investment funds
Loading price data...
--
--

Price Chart

Open
988.77
High
992.00
Low
980.00
Close
988.53
Change
+6.00 (0.61%)
Volume
35,172

Recent RNS announcements

17 Apr 202610:57:11Net Asset Value(s)
16 Apr 202610:51:13Net Asset Value(s)
15 Apr 202611:36:43Net Asset Value(s)
14 Apr 202611:41:49Net Asset Value(s)
13 Apr 202611:51:43Net Asset Value(s)

Annual Reports

6 Nov 2025Annual Financial Report
5 Nov 2024Annual Financial Report
15 Nov 2022Annual Report

Directors (20+)

MP
Mr. P. J. DaviesDirector
–
LD
Lord Davies of AbersochDirector
–
MW
Mr. W. J. DaviesDirector
–
NM
N. M. RothschildDirector
–
MQ
Mr. Q. J. DaviesDirector
–

In the Press

8 Apr 2026Morning briefing: FTSE confirms Vietnams promotion to emerging market; Intl Biotechnology hails frenetic dealmaking” after Soleno bid; plus 3i GroupQuotedData
7 Apr 2026Boost for IBT as Soleno agrees takeoverSharesify
26 Mar 2026Morning briefing: SpaceX to file IPO prospectus; 3i falls on Action update; Intl Biotechnology boosted by Terns bid; Golden Prospect considers management proposalsQuotedData
10 Jul 2023Industry M&A remains a key driverHardman & Co.
8 Dec 2022Low FDA activity may drive further M&AHardman & Co.
30 Jun 2022M&A activity on the riseHardman & Co.
3 Dec 2021Access to fast-growing biotechnology companiesHardman & Co.
6 Jul 2021Investing in a broad spectrum of the drug industryHardman & Co.

Company details

The International Biotechnology Trust provides investors with an actively managed and diversified fund that enables them to tap into the rapidly expanding biotechnology industry.

Industry
Financials
Sector
Financial Services
LEI
213800N1QUJ744P76D11
Region
Europe
Admission date
6 May 1994
Website
ibtplc.com

Investment Trust · as at 30 Mar 2026

NAV per Share
927.45p
Discount/Premium
+6.5%

NAV History

Feb 2025–Jun 2025 · Daily

Shares details

Shares in issue
41,383,817
Total Voting Rights
31,827,834
Treasury Shares
9,555,983
Last updated: 17 April 2026

Recent Buybacks

02/04/2026
30,000£280,200
01/04/2026
30,000£278,014
25/11/2025
25,849£235,709
19/11/2025
100,000£902,680
11/11/2025
22,500£190,800

Instrument details

ISIN
GB0004559349
Exchange
XLON
Market
Main Market
Market Segment
SSMM
Market Sector
SSC5
Security Description
Ordinary Shares of 25p each; fully paid
Listing Category
Closed-ended investment funds
Share Price988.53p
Day Change+6.00p(+0.61%)
Market Cap£409.1m
17 Apr 15:29
Market closed
Share Price988.53p
Day Change+6.00p(+0.61%)
Market Cap£409.1m
17 Apr 15:29
Market closed